Cell therapy with autologous mesenchymal stem cells-how the disease process impacts clinical considerations

Cytotherapy

Volumn 15, Issue 8, 2013, Pages 893-904

  Wang, Jin ^a   Liao, Lianming ^b   Wang, Shuiliang ^a   Tan, Jianming ^a  

^a XIAMEN UNIVERSITY   (China)

^b FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Bone marrow; Cell therapy; Hematopoietic stem cell; Mesenchymal stromal cell

Indexed keywords

CARBAMATE PESTICIDE; CARBOPLATIN; CISPLATIN; CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; ETOPOSIDE; IMMUNOSUPPRESSIVE AGENT; INSECTICIDE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID; NICOTINE; ORGANOPHOSPHATE INSECTICIDE; TACROLIMUS; THIOTEPA; VINCRISTINE;

AGING; AMYOTROPHIC LATERAL SCLEROSIS; APLASTIC ANEMIA; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENVIRONMENTAL IMPACT; HEMATOLOGIC DISEASE; HEPATITIS B; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SEX; SIGNAL TRANSDUCTION; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; TELOMERE HOMEOSTASIS; TUMOR MICROENVIRONMENT; AUTOTRANSPLANTATION; BIOLOGICAL THERAPY; BONE MARROW; BONE MARROW CELL; CELL AGING; CELL THERAPY; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLIC DISORDER; METHODOLOGY; AUTOIMMUNE DISEASES; HEMATOLOGIC DISEASES; METABOLIC DISEASES; PROCEDURES;

BONE MARROW; CELL THERAPY; HEMATOPOIETIC STEM CELL; MESENCHYMAL STROMAL CELL;

AUTOIMMUNE DISEASES; BONE MARROW CELLS; CELL AGING; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; METABOLIC DISEASES; TRANSPLANTATION, AUTOLOGOUS;

EID: 84893510346     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.01.218     Document Type: Review

References (100)

1. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
2. da Silva Meirelles L., Chagastelles P.C., Nardi N.B. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. JCell Sci 2006, 119:2204-2213.
3. Nauta A.J., Westerhuis G., Kruisselbrink A.B., Lurvink E.G., Willemze R., Fibbe W.E. Donor derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006, 108:2114-2120.
4. Koppula P.R., Chelluri L.K., Polisetti N., Vemuganti G.K. Histocompatibility testing of cultivated human bone marrow stromal cells: a promising step towards pre-clinical screening for allogeneic stem cell therapy. Cell Immunol 2009, 259:61-65.
5. Tan J., Wu W., Xu X., Liao L., Zheng F., Messinger S., et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012, 307:1169-1177.
6. Wang J., Liao L., Tan J. Mesenchymal-stem-cell-based experimental and clinical trials: current status and open questions. Expert Opin Biol Ther 2011, 11:893-909.
7. Heeschen C., Lehmann R., Honold J., Assmus B., Aicher A., Walter D.H., et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 2004, 109:1615-1622.
8. Yu J.M., Wu X., Gimble J.M., Guan X., Freitas M.A., Bunnell B.A. Age-related changes in mesenchymal stem cells derived from rhesus macaque bone marrow. Aging Cell 2011, 10:66-79.
9. Xin Y., Wang Y.M., Zhang H., Li J., Wang W., Wei Y.J., et al. Aging adversely impacts biological properties of human bone marrow-derived mesenchymal stem cells: implications for tissue engineering heart valve construction. Artif Organs 2010, 34:215-222.
10. Stolzing A., Jones E., McGonagle D., Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 2008, 129:163-173.
11. Fan M., Chen W., Liu W., Du G.Q., Jiang S.L., Tian W.C., et al. The effect of age on the efficacy of human mesenchymal stem cell transplantation after a myocardial infarction. Rejuvenation Res 2010, 13:429-438.
12. Caplan A.I. Why are MSCs therapeutic? New data: new insight. JPathol 2009, 217:318-324.
13. Stenderup K., Justesen J., Clausen C., Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003, 33:919-926.
14. Zhou S., Greenberger J.S., Epperly M.W., Goff J.P., Adler C., Leboff M.S., et al. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell 2008, 7:335-343.
15. Tokalov S.V., Grüner S., Schindler S., Wolf G., Baumann M., Abolmaali N. Age-related changes in the frequency of mesenchymal stem cells in the bone marrow of rats. Stem Cells Dev 2007, 16:439-446.
16. Wilson A., Shehadeh L.A., Yu H., Webster K.A. Age-related molecular genetic changes of murine bone marrow mesenchymal stem cells. BMC Genomics 2010, 11:229.
17. Asumda F.Z., Chase P.B. Age-related changes in rat bone-marrow mesenchymal stem cell plasticity. BMC Cell Biol 2011, 12:44.
18. Alt E.U., Senst C., Murthy S.N., Slakey D.P., Dupin C.L., Chaffin A.E., et al. Aging alters tissue resident mesenchymal stem cell properties. Stem Cell Res 2012, 8:215-225.
19. Tokalov S.V., Gruener S., Schindler S., Iagunov A.S., Baumann M., Abolmaali N.D. Anumber of bone marrow mesenchymal stem cells but neither phenotype nor differentiation capacities changes with age of rats. Mol Cells 2007, 24:255-260.
20. Seebach C., Henrich D., Tewksbury R., Wilhelm K., Marzi I. Number and proliferative capacity of human mesenchymal stem cells are modulated positively in multiple trauma patients and negatively in atrophic nonunions. Calcif Tissue Int 2007, 80:294-300.
21. Strube P., Mehta M., Baerenwaldt A., Trippens J., Wilson C.J., Ode A., et al. Sex-specific compromised bone healing in female rats might be associated with a decrease in mesenchymal stem cell quantity. Bone 2009, 45:1065-1072.
22. Katsara O., Mahaira L.G., Iliopoulou E.G., Moustaki A., Antsaklis A., Loutradis D., et al. Effects of donor age, gender, and in vitro cellular aging on the phenotypic, functional, and molecular characteristics of mouse bone marrow-derived mesenchymal stem cells. Stem Cells Dev 2011, 20:1549-1561.
23. Crisostomo P.R., Wang M., Herring C.M., Markel T.A., Meldrum K.K., Lillemoe K.D., et al. Gender differences in injury induced mesenchymal stem cell apoptosis and VEGF, TNF, IL-6 expression: role of the 55 kDa TNF receptor (TNFR1). JMol Cell Cardiol 2007, 42:142-149.
24. Yu H.P., Shimizu T., Choudhry M.A., Hsieh Y.C., Suzuki T., Bland K.I., et al. Mechanism of cardioprotection following trauma-hemorrhagic shock by a selective estrogen receptor-beta agonist: up-regulation of cardiac heat shock factor-1 and heat shock proteins. JMol Cell Cardiol 2006, 40:185-194.
25. Szalay L., Shimizu T., Schwacha M.G., Choudhry M.A., Rue L.W., Bland K.I., et al. Mechanism of salutary effects of estradiol on organ function after trauma-hemorrhage: upregulation of heme oxygenase. Am J Physiol Heart Circ Physiol 2005, 289:H92-H98.
26. Crisostomo P.R., Markel T.A., Wang M., Lahm T., Lillemoe K.D., Meldrum D.R. In the adult mesenchymal stem cell population, source gender is a biologically relevant aspect of protective power. Surgery 2007, 142:215-221.
27. Erwin G.S., Crisostomo P.R., Wang Y., Wang M., Markel T.A., Guzman M., et al. Estradiol-treated mesenchymal stem cells improve myocardial recovery after ischemia. JSurg Res 2009, 152:319-324.
28. Yun S.P., Lee M.Y., Ryu J.M., Song C.H., Han H.J. Role of HIF-1alpha and VEGF in human mesenchymal stem cell proliferation by 17beta-estradiol: involvement of PKC, PI3K/Akt, and MAPKs. Am J Physiol Cell Physiol 2009, 296:C317-C326.
29. Hong L., Sultana H., Paulius K., Zhang G. Steroid regulation of proliferation and osteogenic differentiation of bone marrow stromal cells: a gender difference. JSteroid Biochem Mol Biol 2009, 114:180-185.
30. Chen H.Y., Zhang X., Chen S.F., Zhang Y.X., Liu Y.H., Ma L.L., et al. The protective effect of 17β-estradiol against hydrogen peroxide-induced apoptosis on mesenchymal stem cell. Biomed Pharmacother 2012, 66:57-63.
31. Hong L., Colpan A., Peptan I.A. Modulations of 17-beta estradiol on osteogenic and adipogenic differentiations of human mesenchymal stem cells. Tissue Eng 2006, 12:2747-2753.
32. Zhou S., Zilberman Y., Wassermann K., Bain S.D., Sadovsky Y., Gazit D. Estrogen modulates estrogen receptor alpha and beta expression, osteogenic activity, and apoptosis in mesenchymal stem cells (MSCs) of osteoporotic mice. JCell Biochem Suppl 2001, 36(Suppl):144-155.
33. Cha Y., Kwon S.J., Seol W., Park K.S. Estrogen receptor-alpha mediates the effects of estradiol on telomerase activity inhuman mesenchymal stem cells. Mol Cells 2008, 26:454-458.
34. Zhao Z.G., Liang Y., Li K., Li W.M., Li Q.B., Chen Z.C., et al. Phenotypic and functional comparison of mesenchymal stem cells derived from the bone marrow of normal adults and patients with hematologic malignant diseases. Stem Cells Dev 2007, 16:637-648.
35. Zhao Z., Tang X., You Y., Li W., Liu F., Zou P. Assessment of bone marrow mesenchymal stem cell biological characteristics and support hemotopoiesis function in patients with chronic myeloid leukemia. Leuk Res 2006, 30:993-1003.
36. Corre J., Mahtouk K., Attal M., Gadelorge M., Huynh A., Fleury-Cappellesso S., et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007, 21:1079-1088.
37. Garderet L., Mazurier C., Chapel A., Ernou I., Boutin L., Holy X., et al. Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma 2007, 48:2032-2041.
38. Li B., Fu J., Chen P., Zhuang W. Impairment in immunomodulatory function of mesenchymal stem cells from multiple myeloma patients. Arch Med Res 2010, 41:623-633.
39. Arnulf B., Lecourt S., Soulier J., Ternaux B., Lacassagne M.N., Crinquette A., et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007, 21:158-163.
40. Garayoa M., Garcia J.L., Santamaria C., Garcia-Gomez A., Blanco J.F., Pandiella A., et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia 2009, 23:1515-1527.
41. Chao Y.H., Peng C.T., Harn H.J., Chan C.K., Wu K.H. Poor potential of proliferation and differentiation in bone marrow mesenchymal stem cells derived from children with severe aplastic anemia. Ann Hematol 2010, 89:715-723.
42. Klaus M., Stavroulaki E., Kastrinaki M.C., Fragioudaki P., Giannikou K., Psyllaki M., et al. Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev 2010, 19:1043-1054.
43. Yoon J.S., Kim E.S., Hwang D.W., Choi J.Y., Kim B.K., Park B.B., et al. Biologic characteristics of bone marrow-derived mesenchymal stem cells from a patient with thalassemia syndrome. Int J Lab Hematol 2011, 33:281-289.
44. Kastrinaki M.C., Sidiropoulos P., Roche S., Ringe J., Lehmann S., Kritikos H., et al. Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis 2008, 67:741-749.
45. Pérez-Simón J.A., Tabera S., Sarasquete M.E., Díez-Campelo M., Canchado J., Sánchez-Abarca L.I., et al. Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy 2009, 11:698-705.
46. Nie Y., Lau C., Lie A., Chan G., Mok M. Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 2010, 19:850-859.
47. Sun L.Y., Zhang H.Y., Feng X.B., Hou Y.Y., Lu L.W., Fan L.M. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 2007, 16:121-128.
48. Larghero J., Farge D., Braccini A., Lecourt S., Scherberich A., Foïs E., et al. Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann Rheum Dis 2008, 67:443-449.
49. Stolzing A., Sellers D., Llewelyn O., Scutt A. Diabetes induced changes in rat mesenchymal stem cells. Cells Tissues Organs 2010, 191:453-465.
50. Kume S., Kato S., Yamagishi S., Inagaki Y., Ueda S., Arima N., et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. JBone Miner Res 2005, 20:1647-1658.
51. Cho G.W., Noh M.Y., Kim H.Y., Koh S.H., Kim K.S., Kim S.H. Bone marrow-derived stromal cells from amyotrophic lateral sclerosis patients have diminished stem cell capacity. Stem Cells Dev 2010, 19:1035-1042.
52. Ferrero I., Mazzini L., Rustichelli D., Gunetti M., Mareschi K., Testa L., et al. Bone marrow mesenchymal stem cells from healthy donors and sporadic amyotrophic lateral sclerosis patients. Cell Transplant 2008, 17:255-266.
53. Mallam E., Kemp K., Wilkins A., Rice C., Scolding N. Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. Mult Scler 2010, 16:909-918.
54. Mazzanti B., Aldinucci A., Biagioli T., Barilaro A., Urbani S., Dal Pozzo S., et al. Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment. JNeuroimmunol 2008, 199:142-150.
55. Zhang Z., Wang X., Wang S. Isolation and characterization of mesenchymal stem cells derived from bone marrow of patients with Parkinson's disease. In Vitro Cell Dev Biol Anim 2008, 44:169-177.
56. Bacigalupo A., Valle M., Podesta M., Pitto A., Zocchi E., De Flora A., et al. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol 2005, 33:819-827.
57. Wu X., Li Y., Zhu K., Wang Z., Chen S., Yang L. GATA-1, -2 and -3 genes expression in bone marrow microenvironment with chronic aplastic anemia. Hematology 2007, 12:331-335.
58. Papadaki H.A., Kritikos H.D., Gemetzi C., Koutala H., Marsh J.C., Boumpas D.T., et al. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect. Blood 2002, 99:1610-1619.
59. Yu J., Heck S., Patel V., Levan J., Yu Y., Bussel J.B., et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008, 112:1325-1328.
60. Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008, 26:212-222.
61. Prevosto C., Zancolli M., Canevali P., Zocchi M.R., Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 2007, 92:881-888.
62. Yang K., Wang X.Q., He Y.S., Lu L., Chen Q.J., Liu J., et al. Advanced glycation end products induce chemokine/cytokine production via activation of p38 pathway and inhibit proliferation and migration of bone marrow mesenchymal stem cells. Cardiovasc Diabetol 2010, 9:66.
63. Chen T., Zhou Y., Tan W.S. Influence of lactic acid on the proliferation, metabolism, and differentiation of rabbit mesenchymal stem cells. Cell Biol Toxicol 2009, 25:573-586.
64. Peng L., Li H., Gu L., Peng X.M., Huang Y.S., Gao Z.L. Comparison of biological characteristics of marrow mesenchymal stem cells in hepatitis B patients and normal adults. World J Gastroenterol 2007, 13:1743-1746.
65. Rong Q., Zhang L., Su E., Li J., Li J., Liu Z., et al. Bone marrow-derived mesenchymal stem cells are capable of mediating hepatitis B virus infection in injured tissues. JViral Hepat 2008, 15:607-614.
66. Erhardt L. Cigarette smoking: an undertreated risk factor for cardiovascular disease. Atherosclerosis 2009, 205:23-32.
67. Hoogduijn M.J., Cheng A., Genever P.G. Functional nicotinic and muscarinic receptors on mesenchymal stem cells. Stem Cells Dev 2009, 18:103-112.
68. Ruiz J.P., Pelaez D., Dias J., Ziebarth N.M., Cheun H.S. The effect of nicotine on the mechanical properties of mesenchymal stem cells. Cell Health Cytoskelet 2012, 4:29-35.
69. Kim B.S., Kim S.J., Kim H.J., Lee S.J., Park Y.J., Lee J., et al. Effects of nicotine on proliferation and osteoblast differentiation in human alveolar bone marrow-derived mesenchymal stem cells. Life Sci 2012, 90:109-115.
70. Deng Y., Li T.Q., Yan Y.E., Magdalou J., Wang H., Chen L.B. Effect of nicotine on chondrogenic differentiation of rat bone marrow mesenchymal stem cells in alginate bead culture. Biomed Mater Eng 2012, 22:81-87.
71. Ng T.K., Carballosa C.M., Pelaez D., Wong H.K., Choy K.W., Pang C.P., et al. Nicotine alters microRNA expression and hinders human adult stem cell regenerative potential. Stem Cells Dev 2013, 22:781-790.
72. Zhou Y., Gan Y., Taylor H.S. Cigarette smoke inhibits recruitment of bone-marrow-derived stem cells to the uterus. Reprod Toxicol 2011, 31:123-127.
73. Hoogduijn M.J., Rakonczay Z., Genever P.G. The effects of anticholinergic insecticides on human mesenchymal stem cells. Toxicol Sci 2006, 94:342-350.
74. Compston J.E., Vedi S., Stephen A.B., Bord S., Lyons A.R., Hodges S.J., et al. Reduced bone formation after exposure to organophosphates. Lancet 1999, 354:1791-1792.
75. Banfi A., Bianchi G., Galotto M., Cancedda R., Quarto R. Bone marrow stromal damage after chemo/radiotherapy: occurrence, consequences and possibilities of treatment. Leuk Lymphoma 2001, 42:863-870.
76. Li J., Law H.K., Lau Y.L., Chan G.C. Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents. Br J Haematol 2004, 127:326-334.
77. Koç O.N., Gerson S.L., Cooper B.W., Dyhouse S.M., Haynesworth S.E., Caplan A.I., et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. JClin Oncol 2000, 18:307-316.
78. Mueller L.P., Luetzkendorf J., Mueller T., Reichelt K., Simon H., Schmoll H.J. Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: evidence of resistance to apoptosis induction. Stem Cells 2006, 24:2753-2765.
79. Kemp K., Morse R., Sanders K., Hows J., Donaldson C. Alkylating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells. Ann Hematol 2011, 90:777-789.
80. Kemp K., Morse R., Wexler S., Cox C., Mallam E., Hows J., et al. Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy. Ann Hematol 2010, 89:701-713.
81. Buttiglieri S., Ruella M., Risso A., Spatola T., Silengo L., Avvedimento E.V., et al. The aging effect of chemotherapy on cultured human mesenchymal stem cells. Exp Hematol 2011, 39:1171-1181.
82. Hoogduijn M.J., Crop M.J., Korevaar S.S., Peeters A.M., Eijken M., Maat L.P., et al. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. Transplantation 2008, 86:1283-1291.
83. Poncelet A.J., Nizet Y., Vercruysse J., Hiel A.L., Saliez A., Gianello P. Inhibition of humoral response to allogeneic porcine mesenchymal stem cell with 12 days of tacrolimus. Transplantation 2008, 86:1586-1595.
84. Xu G., Zhang L., Ren G., Yuan Z., Zhang Y., Zhao R.C., et al. Immunosuppressive properties of cloned bone marrow mesenchymal stem cells. Cell Res 2007, 17:240-248.
85. Buron F., Perrin H., Malcus C., Héquet O., Thaunat O., Kholopp-Sarda M.N., et al. Human mesenchymal stem cells and immunosuppressive drug interactions in allogeneic responses: an in vitro study using human cells. Transplant Proc 2009, 41:3347-3352.
86. Buron F., Morelon E., Perrin H., Malcus C., Moulin F.T., Héquet O. Mesenchymal stem cell and immunosuppressive drug interactions. Transplantation 2009, 87:1899-1900.
87. Shi D., Liao L., Zhang B., Liu R., Dou X., Li J., et al. Human adipose tissue-derived mesenchymal stem cells facilitate the immunosuppressive effect of cyclosporin A on T lymphocytes through Jagged-1-mediated inhibition of NF-κB signaling. Exp Hematol 2011, 39:214-224.
88. Maccario R., Podestà M., Moretta A., Cometa A., Comoli P., Montagna D., et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005, 90:516-525.
89. Maccario R., Moretta A., Cometa A., Montagna D., Comoli P., Locatelli F., et al. Human mesenchymal stem cells and cyclosporin A exert a synergistic suppressive effect on in vitro activation of alloantigen-specific cytotoxic lymphocytes. Biol Blood Marrow Transplant 2005, 11:1031-1032.
90. Yang C., Tai M., Chen S., Wang Y., Chen Y., Hsiao J., et al. Labeling of human mesenchymal stem cell: comparison between paramagnetic and superparamagnetic agents. JAppl Phys 2009, 105:07B314. -6.
91. Kim H.S., Oh S.Y., Joo H.J., Son K.R., Song I.C., Moon W.K. The effects of clinically used MRI contrast agents on the biological properties of human mesenchymal stem cells. NMR Biomed 2010, 23:514-522.
92. Sun J.H., Zhang Y.L., Qian S.P., Yu X.B., Xie H.Y., Zhou L., et al. Assessment of biological characteristics of mesenchymal stem cells labeled with superparamagnetic iron oxide particles in vitro. Mol Med Report 2012, 5:317-320.
93. Kostura L., Kraitchman D.L., Mackay A.M., Pittenger M.F., Bulte J.W. Feridex labeling of mesenchymal stem cells inhibits chondrogenesis but not adipogenesis or osteogenesis. NMR Biomed 2004, 17:513-517.
94. Hare J.M., Fishman J.E., Gerstenblith G., DiFede Velazquez D.L., Zambrano J.P., Suncion V.Y., et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012, 308:2369-2379.
95. Tögel F., Cohen A., Zhang P., Yang Y., Hu Z., Westenfelder C. Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cells Dev 2009, 18:475-485.
96. Badiavas A.R., Badiavas E.V. Potential benefits of allogeneic bone marrow mesenchymal stem cells for wound healing. Expert Opin Biol Ther 2011, 11:1447-1454.
97. Ferreira L., Karp J.M., Nobre L., Langer R. New opportunities: the use of nanotechnologies to manipulate and track stem cells. Cell Stem Cell 2008, 3:136-146.
98. Ranganath S.H., Levy O., Inamdar M.S., Karp J.M. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 2012, 10:244-258.
99. Bunnell B.A., Betancourt A.M., Sullivan D.E. New concepts on the immune modulation mediated by mesenchymal stem cells. Stem Cell Res Ther 2010, 1:34.
100. Waterman R.S., Tomchuck S.L., Henkle S.L., Betancourt A.M. Anew mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One 2010, 5:e10088.